Skip to content
OpenCapital
Get started

Nuvation Bio NUVB EBITDA

Discontinued — last reported Q1 '26

EBITDA at other companies

Immunome logo
ImmunomeIMNM
-$58.73M-33.4%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.67M+30.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$132M-10.9%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$30.2M+63.9%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
——
Pfizer logo
PfizerPFE
——

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Calculated from Nuvation Bio’s reported figures.

$3.9Mebit+
$536.0KDepreciation Depletion & Amortization
=$4.42M

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's EBITDA?
Nuvation Bio (NUVB) reported EBITDA of $4.42M in Q1 2026.
How has Nuvation Bio's EBITDA changed year-over-year?
Nuvation Bio's EBITDA increased by 107.5% year-over-year, from -$58.69M to $4.42M.
What is the long-term trend for Nuvation Bio's EBITDA?
Over 4 years (2021 to 2025), Nuvation Bio's EBITDA has grown at a 22.7% compound annual growth rate (CAGR), from -$93.13M to -$211.33M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.